One Country. Three Markets

In the past few episodes, now that we have stratified Indian companies on R&D focus (global innovation, India-specific, and pure play generics), and CDMO players especially after the DOD 1260H list update featuring WuXi Apptech, let us think of the front end market. On one hand we see a handful of Indian pharma majors investing in global research, and likely to embed AI into discovery, manufacturing and distribution processes. Global innovators are using AI and other tech to ease out the costs of discovery and in the future are likely to compete with Indian majors for this vast market, of course with portfolios that are vastly differentiated and difficult to copy (biologics, CGT etc). On the other hand, we have 3 Indias in one country - India 1 (10% of the super rich) which is 100-140 miillion people, India 2 - 23% of the middle which is 300m poeple and India 3 which is ~67% of the rest (approx 1B people). These three India’s need different products, prices, promotion and places to access medicine and healthcare. This episode deals with how pharma (global + local companies) will pan out in the next 5-10 years to cater to the three Indias while keeping their aspirations, investments across the value chain and product-market fit for the three Indias? How will companies segment these markets and what is their likely GTM strategy? Listen in! This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com